Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDeltex Medical Regulatory News (DEMG)

  • There is currently no data for DEMG

Director/PDMR Shareholding

1 Jul 2008 14:25

RNS Number : 0400Y
Deltex Medical Group PLC
01 July 2008
 



Deltex Medical Group plc

Grant of options

1 July 2008 - Deltex Medical Group plc ("the Company"), the UK's leading haemodynamic monitoring company, announces that the Board yesterday approved the issue of share options to its executive members.

The Board has approved the issue of contractual share options to Andy Hill, Chief Executive, and Ewan Phillips, Finance Director, under the Company's 2001 Executive Share Option Scheme as follows:

Name

No. of options

Exercise

Price £

Exercise period from

Exercise period to

 

 

 

 

 

Andy Hill

500,000

0.185

30 June 2011

29 June 2018

 

 

 

 

 

Ewan Phillips

500,000

0.185

30 June 2011

29 June 2018

In addition, the Company's 2003 Enterprise Management Incentive Scheme ('EMI Scheme') allows directors and employees who have earned performance related bonus payments under the terms of their employment to sacrifice their entitlement to cash payment in return for share options at the nominal value of 1p per share. The EMI Scheme is designed to allow managers to align their interests with those of shareholders by building a meaningful equity interest in the Company while preserving the Company's cash resources for investment in its operations. In the event that the share price on exercise and sale of an EMI Scheme option share is higher than at the date of bonus sacrifice, the EMI Scheme is potentially tax efficient for the scheme member. However, if the share price on exercise and sale of an EMI Scheme option share is lower than at the date of award, the individual will realise an amount after tax that is lower than the amount of bonus originally sacrificed.

Andy Hill has elected to sacrifice part (£20,000) of the performance bonus and Ewan Phillips has elected to sacrifice the whole (£60,000) of the performance bonus awarded by the Company's Remuneration Committee in respect of the year ended 31 December 2007, resulting in awards of options under the EMI Scheme as follows

 

Name

No. of options

Exercise

Price £

Exercise period from

Exercise period to

 

 

 

 

 

Andy Hill

114,286

0.01

See note (a)

29 June 2018

 

 

 

 

 

Ewan Phillips

342,857

0.01

See note (a)

29 June 2018

 

Note (a). Date of announcement of preliminary results for the year ended 31 December 2008.

  In addition to the options outlined above, Mr Hill has an interest in the following:

Name

No. of options

Exercise

Price £

Exercise period from

Exercise period to

Executive Share Option Scheme

200,000

0.25

27 November 2005

26 November 2012

 

200,000

0.15

28 October 2006

27 October 2013

400,000

0.24

12 October 2007

11 October 2014

400,000

0.2075

28 March 2009

27 March 2016

400,000

0.295

29 June 2010

28 June 2017

EMI Scheme

333,333

0.01

24 March 2004

27 October 2013

 

 156,739

0.01

15 March 2005

11 October 2014

154,085

0.01

15 March 2007

19 May 2016

314,615

0.01

27 March 2008

28 June 2017

In addition to the options outlined above, Mr Phillips has an interest in the following:

Name

No. of options

Exercise

Price £

Exercise period from

Exercise period to

Executive Share Option Scheme

100,000

0.25

7 November 2004

6 November 2011

60,000

0.25

27 November 2005

26 November 2012

 

120,000

0.15

28 October 2006

27 October 2013

400,000

0.24

12 October 2007

11 October 2014

400,000

0.2075

28 March 2009

27 March 2016

400,000

0.295

29 June 2010

28 June 2017

EMI Scheme

583,333

0.01

24 March 2004

27 October 2013

 

 156,739

0.01

15 March 2005

11 October 2014

259,225

0.01

15 March 2007

19 May 2016

235,962

0.01

27 March 2008

28 June 2017

Mr Hill also has a beneficial interest in 179,334 ordinary shares in the Company representing 0.18 per cent of the issued ordinary share capital of the Company.

 

Mr Phillips also has a beneficial interest in 977,156 ordinary shares in the Company representing 0.97 per cent of the issued ordinary share capital of the Company.

All shares and options relate to ordinary 1p shares.

For further information, please contact:-

Deltex Medical Group plc 01243 774 837

Nigel Keen, Chairman  njk@deltexmedical.com

Andy Hill, Chief Executive ahill@deltexmedical.com

Ewan Phillips, Finance Director eap@deltexmedical.com 

Gavin Anderson & Company 0207 554 1400

Deborah Walter dwalter@gavinanderson.co.uk

Robert Speed rspeed@gavinanderson.co.uk

Charles Stanley Securities 020 7149 6000

(Nominated Adviser)

Philip Davies philip.davies@csysecurities.com 

Russell Cook russell.cook@csysecurities.com 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSILFFVDIILIIT
Date   Source Headline
21st Feb 20257:00 amRNSCancellation - Deltex Medical Group Plc
12th Feb 20251:26 pmRNSResult of General Meeting
11th Feb 20256:09 pmRNSHolding in Company
11th Feb 20254:29 pmRNSHolding(s) in Company
10th Feb 20257:00 amRNSHolding in Company
5th Feb 202510:35 amRNSHolding(s) in Company
29th Jan 20253:07 pmRNSHolding(s) in Company
21st Jan 20257:00 amRNSProposed cancellation of trading on AIM
20th Jan 20254:28 pmRNSHolding(s) in Company
20th Jan 20257:00 amRNSHolding(s) in Company
16th Jan 20257:00 amRNSYear-end trading update and proposed cancellation
2nd Dec 20243:20 pmRNSHolding in Company
23rd Sep 20247:00 amRNSInterim results to 30 June 2024
11th Jul 202412:29 pmRNSHolding in Company
10th Jul 202411:46 amRNSHolding in Company
4th Jul 20247:00 amRNSHalf-year Trading Update
12th Jun 20247:00 amRNSNew share plans and grant of share options
4th Jun 20247:00 amRNSAward to NHS Supply Chain Framework Agreement
8th May 202412:50 pmRNSResult of Annual General Meeting
8th May 20247:00 amRNSChairman’s Statement to the Annual General Meeting
8th Apr 20245:03 pmRNSHolding(s) in Company
8th Apr 20247:00 amRNSPosting of Annual Report & Notice of AGM
28th Mar 20247:00 amRNSResults for the year ended 31 December 2023
2nd Feb 20245:11 pmRNSHolding(s) in Company
31st Jan 20245:00 pmRNSTotal Voting Rights
18th Jan 20245:01 pmRNSIssue of Equity
18th Jan 20247:00 amRNSYear-end trading update
4th Dec 20237:00 amRNSCommercial update, board changes & new auditor
18th Sep 20237:00 amRNSInterim results to 30 June 2023
31st Aug 20235:00 pmRNSTotal Voting Rights
2nd Aug 20236:23 pmRNSHolding(s) in Company
2nd Aug 20235:32 pmRNSHolding(s) in Company
2nd Aug 20238:00 amRNSFundraising completion, trading restoration & TVR
2nd Aug 20237:30 amRNSRestoration - Deltex Medical Group PLC
1st Aug 202310:04 amRNSResult of General Meeting
24th Jul 20237:00 amRNSResult of Retail Offer
18th Jul 20234:47 pmRNSExtension of Retail Offer Closing Time
14th Jul 20236:03 pmRNSRetail offer to raise up to £500,000
14th Jul 20236:01 pmRNSPlacing, Subscription and Retail Offer
10th Jul 20237:00 amRNSRelease of new next generation TrueVue System
6th Jul 20237:13 amRNSHalf-year Trading Update & Potential Fundraise
26th Jun 20237:30 amRNSSuspension - Deltex Medical Group PLC
26th Jun 20237:00 amRNSTrading update and suspension of trading on AIM
19th May 20231:35 pmRNSHolding(s) in Company
17th May 20233:24 pmRNSResult of AGM
17th May 20237:00 amRNSChairman’s Statement to the Annual General Meeting
28th Apr 20235:00 pmRNSTotal Voting Rights
25th Apr 20237:00 amRNSNew monitor launch update & new loan facility
11th Apr 20235:43 pmRNSIssue of Equity
30th Mar 20237:00 amRNSResults for the year ended 31 December 2022

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.